Abstract
BackgroundAMG 119 is a CAR-T cell therapy that targets delta-like ligand 3 (DLL3), an inhibitory Notch ligand that is expressed on the surface of most SCLC cells. In preclinical studies,...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have